GlassScriptPhysician profile
Judith J Williams
NPI 1912906942
$1,849.70
in general payments reported to CMS, 2019-2025
31 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $138 · 2021: $310 · 2022: $432 · 2023: $448 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $494 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $493.85 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $625.05 | 2019-2023 | Liletta |
| Astellas Pharma US INC | $218.03 | 2019-2023 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $96.56 | 2025 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $91.00 | 2019-2023 | |
| Channel Medsystems, INC. | $83.17 | 2023 | |
| Exeltis, USA INC. | $82.48 | 2019-2023 | Slynd |
| Pfizer INC. | $81.84 | 2019-2022 | |
| Novo Nordisk INC | $62.11 | 2023-2025 | Wegovy |
| Daiichi Sankyo INC. | $59.34 | 2022-2023 | Injectafer |
| Hologic Sales and Service, LLC | $47.67 | 2022 | |
| Emd Serono, INC. | $44.62 | 2021 | |
| Scynexis, INC. | $41.35 | 2022 | |
| Boston Scientific Corporation | $33.64 | 2019 | |
| Medtronic, INC. | $28.43 | 2023 | Truclear |
| Pacira Pharmaceuticals Incorporated | $26.25 | 2025 | Exparel |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $25.39 | 2021 | |
| Shield Therapeutics INC | $24.48 | 2023 | Accrufer |
| Aspira Women'S Health INC | $21.91 | 2021 | |
| Coopersurgical, INC. | $19.06 | 2023 | Paragard T 380a |
| Minerva Surgical, INC | $13.59 | 2021 | |
| Mylan Pharmaceuticals INC. | $13.36 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.08 | 2020 | |
| Mayne Pharma Commercial LLC | $13.06 | 2021 | |
| Lupin INC. | $12.43 | 2021 | |
| Avion Pharmaceuticals | $12.41 | 2021 | |
| Agile Therapeutics, INC. | $12.28 | 2022 | |
| Amgen INC. | $12.26 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.04 | 2019 | |
| Allergan, INC. | $11.50 | 2019 | |
| Vertical Pharmaceuticals, LLC | $11.31 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.